Skip to main content
. 2019 Jun 14;20(12):2909. doi: 10.3390/ijms20122909

Figure 2.

Figure 2

Reactivity of GAD65 antibodies to N- and C-terminally truncated peptides. (a) reactivity of the mAb GAD65 to N-terminally truncated peptides. Peptide 1 (MASPGSGFWSFGSEDGSGDS) was used as positive control; (b) reactivity of the mAb GAD65 to C-terminally truncated peptides. Peptide 1 was used as positive control; (c) reactivity of the pAb GAD65 to N-terminally truncated peptides of epitope 1. Peptide 52 (PSLRTLEDNEERMSRLSKVA) was used as positive control; (d) reactivity of the pAb GAD65 to C-terminally truncated peptides of epitope 1. Peptide 52 was used as positive control; (e) reactivity of the pAb GAD65 to N-terminally truncated peptides of epitope 2. Peptide 55 (GTTMVSYQPLGDKVNFFRMV) was used as positive control; (f) reactivity of the pAb GAD65 to C-terminally truncated peptides of epitope 2. Peptide 55 was used as positive control.